Test helpful for SLN-negative, stage I to IIA and thin tumors
Earlier detection of certain cancers a likely result
Toward detailed, personalized maps of identified and interpreted genomic variation
Refractory patients respond to combination therapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A closer look at other T-cell subsets
First agent in a new class of noncytotoxic cancer drugs
Understanding resistance in PARP inhibitor therapy
More time on drug may be needed
Data may lead to better treatment
Advertisement
Advertisement